Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer (original) (raw)
Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines
د.صلاح مبروك خلاف
Advances in Breast Cancer Research, 2020
View PDFchevron_right
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis
A. Galardi, Giampaolo Biti, Carla Cardillo, Monica Mangoni
Tumori
View PDFchevron_right
Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer
Adam Januszewski
Clinical Breast Cancer, 2014
View PDFchevron_right
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
Faby Rivera
Cancer Chemotherapy and Pharmacology, 2006
View PDFchevron_right
Current Status of Liposomal Anthracycline Therapy in Metastatic Breast Cancer
edgardo Rivera
Clinical Breast Cancer, 2003
View PDFchevron_right
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase...
Sergei Tjulandin
Journal of Clinical Oncology, 2009
View PDFchevron_right
Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines
Louise Provencher
Journal of Clinical Oncology, 2009
View PDFchevron_right
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Sihem Ait-Oudhia
Breast Cancer: Targets and Therapy, 2018
View PDFchevron_right
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil") versus conventional doxorubicin for first-line treatment of metastatic breast cancer
E. Grischke
Annals of Oncology, 2004
View PDFchevron_right
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer
Andrea Rocca
Cancer Chemotherapy and Pharmacology, 2010
View PDFchevron_right
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
Lourdes Calvo
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
Mauro Mansutti
The Breast, 2010
View PDFchevron_right
Pegylated Liposomal Doxorubicin (Caelyx ® ) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
Carla De Luca Cardillo
Journal of Chemotherapy, 2011
View PDFchevron_right
Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Dominique Jaubert
European Journal of Cancer, 2011
View PDFchevron_right
Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2Positive Breast Cancer
Susana Campos
Clinical Breast Cancer, 2009
View PDFchevron_right
Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update
edgardo Rivera
View PDFchevron_right
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study
Amparo Latorre
Annals of Oncology, 2007
View PDFchevron_right
Maintenance Treatment with Pegylated Liposomal Doxorubicin vs. Observation following Induction Chemotherapy for Metastatic Breast Cancer: GEICAM …
Miguel Martín
View PDFchevron_right
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
د.صلاح مبروك خلاف
Journal of the Egyptian National Cancer Institute, 2020
View PDFchevron_right
Role of liposomal anthracyclines in breast cancer
Nicola Silvestris
Annals of Oncology, 2007
View PDFchevron_right
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
Giuseppe Viale
Clinical Breast Cancer, 2010
View PDFchevron_right
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
Miguel Marsal Martín
Breast Cancer Research and Treatment, 2010
View PDFchevron_right
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Arnd Nusch
BMC Cancer, 2010
View PDFchevron_right
Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
Cesar Mendiola
Clinical and Translational Oncology, 2012
View PDFchevron_right
Phase II Study of Pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with Previous Anthracycline Exposure
Antonio Casado
Clinical Breast Cancer, 2004
View PDFchevron_right
Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer
Susana Campos
2003
View PDFchevron_right
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
ahmed reda
Biomedicine & Pharmacotherapy, 2017
View PDFchevron_right
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials
Zhila Taherzadeh
Cancer Gene Therapy, 2017
View PDFchevron_right